Oncotarget

Research Papers:

Clinicopathological and prognostic significance of c-Met overexpression in breast cancer

Xixi Zhao, Jingkun Qu, Yuxin Hui, Hong Zhang, Yuchen Sun, Xu Liu, Xiaoyao Zhao, Zitong Zhao, Qian Yang, Feidi Wang and Shuqun Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:56758-56767. https://doi.org/10.18632/oncotarget.18142

Metrics: PDF 2372 views  |   HTML 2891 views  |   ?  


Abstract

Xixi Zhao1,*, Jingkun Qu2,*, Yuxin Hui3, Hong Zhang1, Yuchen Sun4, Xu Liu2, Xiaoyao Zhao1, Zitong Zhao1, Qian Yang1, Feidi Wang1 and Shuqun Zhang1

1Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, P.R. China

2The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

3The School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China

4The Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Shuqun Zhang, email: [email protected]

Keywords: breast cancer, c-Met, prognosis, meta-analysis

Received: April 05, 2017    Accepted: April 27, 2017    Published: May 24, 2017

ABSTRACT

Background: c-Met has been shown to promote organ development and cancer progression in many cancers. However, clinicopathological and prognostic value of c-Met in breast cancer remains elusive.

Methods: PubMed and EMBASE databases were searched for eligible studies. Correlation of c-Met overexpression with survival data and clinicopathological features was analyzed by using hazard ratio (HR) or odds ratio (OR) and fixed-effect or random-effect model according to heterogeneity. All statistical tests were two-sided.

Results: 32 studies with 8281 patients were analyzed in total. The c-Met overexpression was related to poor OS (overall survival) (HR=1.65 (1.328, 2.051)) of 18 studies with 4751 patients and poor RFS/DFS (relapse/disease free survival) (HR=1.53 (1.20, 1.95)) of 12 studies with 3598 patients. Subgroup analysis according to data source/methods/ethnicity showed c-Met overexpression was related to worse OS and RFS/DFS in Given by author group, all methods group and non-Asian group respectively. Besides, c-Met overexpression was associated with large tumor size, high histologic grade and metastasis.

Conclusions: Our results showed that c-Met overexpression was connected with poor survival rates and malignant activities of cancer, including proliferation, migration and invasion, which highlighted the potential of c-Met as significant candidate biomarker to identify patients with breast cancer at high risk of tumor death.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18142